cinacalcet 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
calcium-sensing receptors (CaSR) agonists	647	226256-56-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cinacalcet mimpara cinacalcet hydrochloride sensipar AMG 073 AMG-073 KRN1493 cinacalcet HCl	Molecular weight: 357.42 Formula: C22H22F3N CLOGP: 6.35 LIPINSKI: 1 HAC: 1 HDO: 1 TPSA: 12.03 ALOGS: -6.81 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cinacalcet
mimpara
cinacalcet hydrochloride
sensipar
AMG 073
AMG-073
KRN1493
cinacalcet HCl

Molecular weight: 357.42
Formula: C22H22F3N
CLOGP: 6.35
LIPINSKI: 1
HAC: 1
HDO: 1
TPSA: 12.03
ALOGS: -6.81
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
60	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	7.19 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	20 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	17.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	18.30 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.05 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	19.90 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Oct. 22, 2004	EMA
March 8, 2004	FDA	AMGEN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hospitalisation	8523.27	22.01	2557	24047	65380	50513140
Product dose omission issue	6899.87	22.01	2810	23794	181028	50397492
Laboratory test abnormal	6124.59	22.01	1572	25032	21636	50556884
Adverse drug reaction	1286.00	22.01	611	25993	54611	50523909
Intentional product misuse	895.27	22.01	453	26151	46281	50532239
Blood parathyroid hormone increased	844.88	22.01	213	26391	2641	50575879
Blood parathyroid hormone abnormal	478.18	22.01	85	26519	130	50578390
Hospice care	339.38	22.01	124	26480	5648	50572872
Arteriovenous fistula site complication	322.26	22.01	70	26534	423	50578097
Adverse event	253.94	22.01	199	26405	43564	50534956
Living in residential institution	248.37	22.01	56	26548	411	50578109
Calciphylaxis	225.77	22.01	75	26529	2563	50575957
Hypocalcaemia	223.89	22.01	152	26452	26664	50551856
Death	219.27	22.01	509	26095	324870	50253650
Blood calcium increased	208.77	22.01	95	26509	7624	50570896
Rehabilitation therapy	208.66	22.01	60	26544	1253	50577267
Decreased appetite	199.51	22.01	369	26235	200554	50377966
Hypophagia	184.81	22.01	137	26467	27591	50550929
Nausea	180.11	22.01	788	25816	704610	49873910
Malaise	179.67	22.01	481	26123	335051	50243469
Transplant	165.28	22.01	43	26561	607	50577913
Blood calcium decreased	148.60	22.01	107	26497	20599	50557921
Blood calcium abnormal	147.77	22.01	44	26560	1042	50577478
Renal transplant	147.00	22.01	45	26559	1174	50577346
Vomiting	136.02	22.01	539	26065	460219	50118301
Blood parathyroid hormone decreased	130.15	22.01	67	26537	7047	50571473
Parathyroid tumour benign	124.14	22.01	34	26570	590	50577930
Parathyroidectomy	122.60	22.01	28	26576	219	50578301
Unevaluable investigation	122.55	22.01	21	26583	22	50578498
Nephrogenic systemic fibrosis	119.41	22.01	54	26550	4268	50574252
Fatigue	108.57	22.01	128	26476	707473	49871047
Peritonitis bacterial	100.28	22.01	49	26555	4612	50573908
Arthralgia	90.40	22.01	60	26544	438642	50139878
Abdominal discomfort	90.14	22.01	297	26307	231344	50347176
Hungry bone syndrome	89.00	22.01	18	26586	72	50578448
Blood phosphorus increased	86.68	22.01	37	26567	2545	50575975
Rheumatoid arthritis	86.39	22.01	5	26599	202545	50375975
Hypercalcaemia	84.19	22.01	81	26523	23271	50555249
Brown tumour	80.54	22.01	15	26589	34	50578486
Gastrointestinal tube insertion	79.65	22.01	27	26577	982	50577538
Mastication disorder	73.70	22.01	30	26574	1830	50576690
Pyrexia	73.02	22.01	56	26548	380147	50198373
Pain	71.45	22.01	122	26482	578781	49999739
Dialysis	70.51	22.01	50	26554	9388	50569132
Joint swelling	70.06	22.01	21	26583	245265	50333255
Skin induration	66.84	22.01	32	26572	2879	50575641
Hyperparathyroidism	63.03	22.01	29	26575	2385	50576135
Blood phosphorus abnormal	62.66	22.01	15	26589	147	50578373
Sinusitis	60.10	22.01	9	26595	170549	50407971
Hepatic enzyme increased	59.77	22.01	3	26601	137377	50441143
Condition aggravated	57.95	22.01	43	26561	297015	50281505
Product use issue	57.25	22.01	6	26598	149469	50429051
Drug ineffective	55.31	22.01	233	26371	819100	49759420
Arteriovenous fistula occlusion	54.38	22.01	16	26588	363	50578157
Arthropathy	54.12	22.01	9	26595	157897	50420623
Toxicity to various agents	50.95	22.01	24	26580	212475	50366045
Systemic lupus erythematosus	50.51	22.01	7	26597	140615	50437905
Parathyroid tumour malignant	50.14	22.01	9	26595	15	50578505
Gastrostomy	49.21	22.01	16	26588	510	50578010
Abdominal pain upper	48.79	22.01	189	26415	159120	50419400
Skin hypertrophy	47.69	22.01	26	26578	3069	50575451
Neutropenia	47.36	22.01	10	26594	147955	50430565
Unevaluable event	46.01	22.01	85	26519	45981	50532539
Skin fibrosis	45.14	22.01	17	26587	842	50577678
Hypervolaemia	44.88	22.01	61	26543	25438	50553082
Blue toe syndrome	44.79	22.01	14	26590	392	50578128
Treatment failure	44.67	22.01	9	26595	137628	50440892
Enteral nutrition	44.50	22.01	9	26595	36	50578484
Therapeutic product effect decreased	43.94	22.01	9	26595	136041	50442479
Peritonitis	43.57	22.01	47	26557	15439	50563081
Skin tightness	42.96	22.01	26	26578	3737	50574783
Stomatitis	41.70	22.01	3	26601	101341	50477179
Injection site pain	41.13	22.01	5	26599	111019	50467501
Glossodynia	40.92	22.01	6	26598	115563	50462957
Hyperphosphataemia	38.25	22.01	19	26585	1852	50576668
Swelling	37.96	22.01	30	26574	200842	50377678
Rash	37.66	22.01	112	26492	437359	50141161
Surgery	37.02	22.01	61	26543	30144	50548376
Drug hypersensitivity	36.58	22.01	47	26557	250963	50327557
Weight increased	35.87	22.01	32	26572	201859	50376661
End stage renal disease	35.21	22.01	27	26577	5710	50572810
Pelvic deformity	34.32	22.01	10	26594	219	50578301
Thyroid operation	33.31	22.01	9	26595	148	50578372
White blood cell count decreased	33.27	22.01	10	26594	116712	50461808
Parathyroid disorder	32.71	22.01	12	26592	552	50577968
Neuropathy peripheral	32.08	22.01	6	26598	96751	50481769
Arteriovenous fistula site infection	31.58	22.01	7	26597	47	50578473
Alanine aminotransferase increased	30.34	22.01	5	26599	88354	50490166
Peritoneal dialysis complication	30.24	22.01	14	26590	1167	50577353
Wrong technique in product usage process	29.91	22.01	80	26524	55430	50523090
Contusion	29.55	22.01	11	26593	112172	50466348
Cerebrovascular accident	29.50	22.01	113	26491	94567	50483953
Parathyroid hyperplasia	29.25	22.01	8	26596	138	50578382
Dyspnoea	28.60	22.01	170	26434	547438	50031082
Joint contracture	28.34	22.01	15	26589	1669	50576851
Product use in unapproved indication	27.86	22.01	13	26591	115806	50462714
Treatment noncompliance	26.85	22.01	53	26551	30097	50548423
Shunt occlusion	26.35	22.01	10	26594	506	50578014
Cardiac operation	26.10	22.01	17	26587	2778	50575742
Hyperparathyroidism tertiary	26.09	22.01	5	26599	14	50578506
Malignant neoplasm progression	25.40	22.01	3	26601	68121	50510399
Dysphagia	25.37	22.01	94	26510	77424	50501096
Adjusted calcium decreased	25.26	22.01	7	26597	127	50578393
Wound	25.25	22.01	12	26592	105782	50472738
Headache	25	22.01	160	26444	506375	50072145
Platelet count decreased	24.70	22.01	11	26593	100715	50477805
Alopecia	23.84	22.01	59	26545	244988	50333532
Aspartate aminotransferase increased	23.50	22.01	6	26598	77992	50500528
Nephrocalcinosis	23.25	22.01	11	26593	963	50577557
Chronic kidney disease-mineral and bone disorder	23.24	22.01	6	26598	82	50578438
Arteriovenous fistula site haemorrhage	23.00	22.01	7	26597	179	50578341
High turnover osteopathy	22.50	22.01	5	26599	34	50578486
Arteriovenous fistula thrombosis	22.49	22.01	7	26597	193	50578327
Wheezing	22.48	22.01	3	26601	62044	50516476

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product dose omission issue	7475.63	21.36	2730	19041	93653	29459103
Hospitalisation	6809.23	21.36	2125	19646	43863	29508893
Laboratory test abnormal	5831.15	21.36	1539	20232	16646	29536110
Adverse drug reaction	1051.37	21.36	457	21314	23563	29529193
Intentional product misuse	726.86	21.36	399	21372	34262	29518494
Blood parathyroid hormone increased	628.67	21.36	155	21616	1200	29551556
Blood parathyroid hormone abnormal	474.19	21.36	85	21686	76	29552680
Arteriovenous fistula site complication	375.68	21.36	82	21689	340	29552416
Adverse event	219.50	21.36	138	21633	15153	29537603
Transplant	212.08	21.36	57	21714	640	29552116
Blood calcium increased	197.03	21.36	78	21693	3141	29549615
Hospice care	190.88	21.36	87	21684	4981	29547775
Hypocalcaemia	190.77	21.36	142	21629	20523	29532233
Parathyroidectomy	183.39	21.36	35	21736	58	29552698
Blood parathyroid hormone decreased	171.26	21.36	50	21721	774	29551982
Living in residential institution	163.30	21.36	39	21732	259	29552497
Abdominal discomfort	162.44	21.36	188	21583	47715	29505041
Blood calcium abnormal	146.15	21.36	39	21732	425	29552331
Nausea	140.80	21.36	499	21272	288756	29264000
Blood calcium decreased	129.55	21.36	82	21689	9100	29543656
Rehabilitation therapy	129.33	21.36	38	21733	602	29552154
Hypophagia	128.06	21.36	113	21658	20759	29531997
Calciphylaxis	120.11	21.36	40	21731	972	29551784
Blood phosphorus increased	117.32	21.36	52	21719	2785	29549971
Renal transplant	112.44	21.36	43	21728	1575	29551181
Vomiting	109.77	21.36	374	21397	211886	29340870
Unevaluable investigation	100.98	21.36	18	21753	15	29552741
Acute kidney injury	90.83	21.36	41	21730	265226	29287530
Parathyroid tumour benign	88.71	21.36	20	21751	99	29552657
Toxicity to various agents	83.17	21.36	14	21757	173647	29379109
Death	82.67	21.36	480	21291	341604	29211152
Hypercalcaemia	78.07	21.36	69	21702	12690	29540066
Abdominal pain upper	76.09	21.36	150	21621	60843	29491913
Malaise	76.07	21.36	274	21497	159328	29393428
Hungry bone syndrome	74.56	21.36	16	21755	60	29552696
Pyrexia	69.29	21.36	66	21705	287556	29265200
Neutropenia	66.74	21.36	9	21762	131702	29421054
Peritonitis bacterial	63.25	21.36	44	21727	5712	29547044
Parathyroid disorder	57.48	21.36	12	21759	38	29552718
Gastrointestinal disorder	55.94	21.36	86	21685	28620	29524136
Surgery	55.33	21.36	55	21716	11724	29541032
Gastrostomy	51.27	21.36	19	21752	637	29552119
Decreased appetite	50.32	21.36	226	21545	145116	29407640
Drug interaction	48.98	21.36	44	21727	197341	29355415
Parathyroid tumour malignant	48.76	21.36	9	21762	11	29552745
Nephrogenic systemic fibrosis	47.73	21.36	32	21739	3910	29548846
Gastrointestinal tube insertion	47.66	21.36	21	21750	1108	29551648
Parathyroid hyperplasia	47.18	21.36	8	21763	3	29552753
Mastication disorder	47.11	21.36	21	21750	1139	29551617
Fatigue	41.67	21.36	109	21662	316712	29236044
Blood phosphorus abnormal	41.54	21.36	11	21760	116	29552640
Adjusted calcium decreased	41.01	21.36	7	21764	3	29552753
Unevaluable event	40.35	21.36	76	21695	29775	29522981
Treatment noncompliance	39.57	21.36	67	21704	24160	29528596
Dialysis	39.55	21.36	43	21728	10165	29542591
Condition aggravated	39.49	21.36	30	21741	146265	29406491
Hyperparathyroidism	38.07	21.36	18	21753	1119	29551637
Gastric disorder	37.88	21.36	43	21728	10661	29542095
Platelet count decreased	37.60	21.36	15	21756	104657	29448099
Dyspnoea	36.72	21.36	121	21650	326611	29226145
Leg amputation	35.68	21.36	21	21750	2043	29550713
Overdose	34.87	21.36	8	21763	79811	29472945
Hyperphosphataemia	34.11	21.36	21	21750	2217	29550539
Alanine aminotransferase increased	33.29	21.36	6	21765	70938	29481818
Disease progression	32.39	21.36	10	21761	81906	29470850
Confusional state	32.29	21.36	28	21743	127849	29424907
Shunt stenosis	31.65	21.36	13	21758	576	29552180
White blood cell count decreased	31.52	21.36	11	21760	83351	29469405
Brown tumour	31.08	21.36	5	21766	0	29552756
Product use in unapproved indication	30.30	21.36	13	21758	86862	29465894
Haemoglobin increased	29.24	21.36	21	21750	2865	29549891
Shunt occlusion	28.86	21.36	13	21758	723	29552033
Peritonitis	28.29	21.36	44	21727	14780	29537976
Skin induration	28.10	21.36	18	21753	2036	29550720
Anaemia	28.01	21.36	67	21704	200884	29351872
Appetite disorder	27.96	21.36	18	21753	2054	29550702
Neuropathy peripheral	27.49	21.36	9	21762	71018	29481738
Pulmonary embolism	27.42	21.36	11	21760	76523	29476233
Hyponatraemia	27.20	21.36	8	21763	67625	29485131
Thyroid operation	27.14	21.36	5	21766	6	29552750
Thrombocytopenia	26.83	21.36	36	21735	134787	29417969
Vestibular neuronitis	25.21	21.36	8	21763	166	29552590
Rhabdomyolysis	24.81	21.36	7	21764	60801	29491955
Hyperparathyroidism secondary	24.78	21.36	14	21757	1261	29551495
Wrong technique in product usage process	24.30	21.36	64	21707	31364	29521392
Aspartate aminotransferase increased	24.14	21.36	7	21764	59718	29493038
Pancytopenia	23.80	21.36	16	21755	83152	29469604
Weight decreased	23.75	21.36	47	21724	150858	29401898
Parathyroid gland enlargement	23.14	21.36	7	21764	123	29552633
Drug effective for unapproved indication	23.06	21.36	14	21757	1441	29551315
Product use issue	22.77	21.36	5	21766	51439	29501317
Nephrocalcinosis	22.46	21.36	10	21761	541	29552215
Tachycardia	22.00	21.36	13	21758	72397	29480359
Dehydration	21.47	21.36	32	21739	114716	29438040

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Laboratory test abnormal	9690.85	16.86	2292	31984	21771	64442685
Hospitalisation	5978.55	16.86	2014	32262	73193	64391263
Product dose omission issue	3137.00	16.86	1678	32598	193069	64271387
Blood parathyroid hormone increased	1010.43	16.86	251	34025	2883	64461573
Blood parathyroid hormone abnormal	742.17	16.86	134	34142	232	64464224
Arteriovenous fistula site complication	716.14	16.86	151	34125	765	64463691
Adverse drug reaction	545.20	16.86	325	33951	45139	64419317
Nausea	459.31	16.86	1168	33108	784632	63679824
Vomiting	367.30	16.86	863	33413	550254	63914202
Decreased appetite	351.78	16.86	575	33701	280714	64183742
Living in residential institution	345.76	16.86	77	34199	524	64463932
Calciphylaxis	309.93	16.86	101	34175	3211	64461245
Rehabilitation therapy	298.95	16.86	82	34194	1416	64463040
Death	280.68	16.86	718	33558	481987	63982469
Abdominal discomfort	269.69	16.86	403	33873	181919	64282537
Hypocalcaemia	269.03	16.86	203	34073	41550	64422906
Blood calcium increased	251.75	16.86	112	34164	8430	64456026
Unevaluable investigation	234.01	16.86	39	34237	28	64464428
Malaise	218.19	16.86	578	33698	395669	64068787
Blood calcium abnormal	197.30	16.86	57	34219	1197	64463259
Parathyroid tumour benign	186.24	16.86	48	34228	644	64463812
Renal transplant	180.16	16.86	61	34215	2187	64462269
Intentional product misuse	177.09	16.86	205	34071	72090	64392366
Muscle spasms	175.32	16.86	288	33988	140735	64323721
Blood phosphorus increased	162.44	16.86	70	34206	4876	64459580
Blood calcium decreased	159.59	16.86	122	34154	25432	64439024
Abdominal pain upper	159.31	16.86	312	33964	174718	64289738
Hungry bone syndrome	150.45	16.86	31	34245	137	64464319
Peritonitis bacterial	149.87	16.86	80	34196	8963	64455493
Blood parathyroid hormone decreased	141.65	16.86	72	34204	7294	64457162
Parathyroidectomy	133.78	16.86	29	34247	171	64464285
Hypercalcaemia	131.57	16.86	119	34157	31297	64433159
Nephrogenic systemic fibrosis	126.30	16.86	62	34214	5830	64458626
Unevaluable event	119.97	16.86	141	34135	50348	64414108
Hyperparathyroidism	102.39	16.86	43	34233	2809	64461647
Toxicity to various agents	97.06	16.86	36	34240	363477	64100979
Brown tumour	92.21	16.86	17	34259	35	64464421
Surgery	91.81	16.86	93	34183	28120	64436336
Adjusted calcium decreased	88.81	16.86	20	34256	144	64464312
Pyrexia	88.63	16.86	100	34176	558544	63905912
Dialysis	84.76	16.86	71	34205	16849	64447607
Transplant	83.05	16.86	27	34249	851	64463605
Febrile neutropenia	82.99	16.86	4	34272	187653	64276803
Parathyroid tumour malignant	81.98	16.86	15	34261	29	64464427
Skin induration	80.82	16.86	41	34235	4134	64460322
Gastrointestinal tube insertion	76.53	16.86	29	34247	1445	64463011
Neutropenia	76.29	16.86	17	34259	239607	64224849
Gastric disorder	75.15	16.86	85	34191	29112	64435344
Shunt occlusion	74.20	16.86	27	34249	1200	64463256
Rheumatoid arthritis	71.08	16.86	4	34272	164290	64300166
Hypophagia	70.85	16.86	96	34180	39491	64424965
Parathyroid disorder	69.81	16.86	20	34256	407	64464049
Gastrostomy	68.13	16.86	24	34252	970	64463486
Condition aggravated	66.58	16.86	60	34216	372366	64092090
Hyperphosphataemia	65.34	16.86	35	34241	3946	64460510
Drug interaction	63.93	16.86	59	34217	362024	64102432
Arthralgia	60.90	16.86	88	34188	442172	64022284
Arteriovenous fistula occlusion	60.65	16.86	19	34257	530	64463926
Fatigue	59.52	16.86	202	34074	748528	63715928
Shunt stenosis	59.06	16.86	22	34254	1045	64463411
Blood phosphorus abnormal	58.72	16.86	16	34260	269	64464187
Acute kidney injury	57.43	16.86	94	34182	449146	64015310
Peritonitis	56.31	16.86	68	34208	24955	64439501
Skin hypertrophy	55.82	16.86	33	34243	4496	64459960
Skin tightness	55.59	16.86	34	34242	4927	64459529
Joint swelling	54.67	16.86	23	34253	215359	64249097
Hypervolaemia	52.70	16.86	82	34194	38203	64426253
Hepatic enzyme increased	50.99	16.86	5	34271	129938	64334518
Leg amputation	50.35	16.86	28	34248	3399	64461057
Diarrhoea	50.19	16.86	595	33681	722109	63742347
Product use issue	49.83	16.86	10	34266	151705	64312751
Peritoneal dialysis complication	49.41	16.86	24	34252	2204	64462252
Sinusitis	49.24	16.86	9	34267	145919	64318537
End stage renal disease	48.46	16.86	42	34234	10433	64454023
Skin fibrosis	45.78	16.86	20	34256	1439	64463017
Injection site pain	44.47	16.86	4	34272	111404	64353052
Alanine aminotransferase increased	43.95	16.86	10	34266	139021	64325435
Pelvic deformity	43.93	16.86	10	34266	76	64464380
Parathyroid gland enlargement	43.58	16.86	11	34265	135	64464321
White blood cell count decreased	43.13	16.86	15	34261	157822	64306634
Appetite disorder	42.87	16.86	32	34244	6429	64458027
Parathyroid hyperplasia	41.92	16.86	11	34265	159	64464297
Platelet count decreased	40.83	16.86	19	34257	167692	64296764
Cardiac operation	40.00	16.86	26	34250	4188	64460268
Blue toe syndrome	39.78	16.86	14	34262	564	64463892
High turnover osteopathy	39.47	16.86	8	34268	32	64464424
Arteriovenous fistula thrombosis	37.12	16.86	13	34263	516	64463940
Parathyroid haemorrhage	36.81	16.86	6	34270	3	64464453
Arteriovenous fistula site infection	36.48	16.86	10	34266	172	64464284
Therapeutic procedure	36.46	16.86	14	34262	723	64463733
Stomatitis	36.45	16.86	7	34269	109598	64354858
Angina pectoris	34.59	16.86	75	34201	45006	64419450
Product use in unapproved indication	34.55	16.86	26	34250	176592	64287864
Shunt infection	34.30	16.86	9	34267	130	64464326
Drug ineffective	33.49	16.86	286	33990	839961	63624495
Neuropathy peripheral	32.39	16.86	11	34265	117514	64346942
Arthropathy	32.18	16.86	12	34264	120955	64343501
Weight increased	31.78	16.86	40	34236	213308	64251148
Wrong technique in product usage process	31.76	16.86	91	34185	64883	64399573
Aspartate aminotransferase increased	31.67	16.86	12	34264	119776	64344680
Joint contracture	31.50	16.86	18	34258	2301	64462155
Nephrocalcinosis	31.49	16.86	15	34261	1319	64463137
Hyperparathyroidism secondary	31.42	16.86	18	34258	2312	64462144
Constipation	31.36	16.86	219	34057	229118	64235338
Treatment noncompliance	30.72	16.86	70	34206	43412	64421044
Fistula repair	30.55	16.86	7	34269	55	64464401
Confusional state	29.41	16.86	59	34217	261085	64203371
Blood pressure increased	29.37	16.86	29	34247	172523	64291933
Rash	29.13	16.86	135	34141	458414	64006042
Paraesthesia	29.11	16.86	145	34131	134377	64330079
Dyspnoea	28.88	16.86	244	34032	718430	63746026
Gastrointestinal disorder	28.87	16.86	109	34167	89600	64374856
Haemoglobin increased	28.50	16.86	23	34253	5178	64459278
Thyroid operation	28.20	16.86	8	34268	157	64464299
Arrhythmia	27.69	16.86	76	34200	52868	64411588
Toe amputation	27.02	16.86	19	34257	3481	64460975
Arteriovenous fistula site haemorrhage	26.70	16.86	9	34267	318	64464138
Therapeutic product effect decreased	26.66	16.86	14	34262	115337	64349119
Hospice care	26.39	16.86	26	34250	7599	64456857
Phosphaturic mesenchymal tumour	26.16	16.86	4	34272	0	64464456
Lower respiratory tract infection	25.82	16.86	9	34267	94605	64369851
Cerebrovascular accident	25.44	16.86	142	34134	137441	64327015
Psoriasis	25.11	16.86	4	34272	71699	64392757
Parathyroid gland operation	24.67	16.86	5	34271	20	64464436
Intentional product use issue	24.47	16.86	10	34266	95354	64369102
Treatment failure	24.42	16.86	16	34260	116800	64347656
Hypercalciuria	24.23	16.86	9	34267	424	64464032
Fibrosis	24.01	16.86	20	34256	4708	64459748
Medical procedure	23.97	16.86	8	34268	274	64464182
Hepatic cyst infection	23.79	16.86	7	34269	157	64464299
Overdose	23.67	16.86	30	34246	159536	64304920
Neoplasm malignant	23.60	16.86	45	34231	24643	64439813
Pain	23.53	16.86	185	34091	553326	63911130
Mucosal inflammation	23.06	16.86	3	34273	62581	64401875
Adverse event	23.00	16.86	59	34217	39430	64425026
Hyperparathyroidism tertiary	22.92	16.86	4	34272	5	64464451
Thrombosis in device	22.79	16.86	20	34256	5051	64459405
Chronic kidney disease-mineral and bone disorder	22.78	16.86	9	34267	502	64463954
Intracardiac mass	22.41	16.86	6	34270	94	64464362
Hypotension	22.18	16.86	304	33972	380670	64083786
Skin hyperpigmentation	22.05	16.86	22	34254	6529	64457927
Wheezing	21.42	16.86	8	34268	80571	64383885
Rhabdomyolysis	21.39	16.86	11	34265	91715	64372741
Blood pressure abnormal	21.39	16.86	32	34244	14403	64450053
Pericarditis	20.77	16.86	4	34272	62512	64401944
Pancytopenia	20.18	16.86	28	34248	143281	64321175
Syncope	20.07	16.86	33	34243	157602	64306854
Foot amputation	20.04	16.86	9	34267	692	64463764
Intermittent claudication	19.98	16.86	15	34261	3039	64461417
Deep vein thrombosis	19.91	16.86	16	34260	105166	64359290
Glossodynia	19.75	16.86	5	34271	64691	64399765
Parathyroid cyst	19.62	16.86	3	34273	0	64464456
Drug hypersensitivity	19.58	16.86	63	34213	237752	64226704
Liver function test abnormal	19.32	16.86	4	34272	59397	64405059
Swelling	19.07	16.86	35	34241	160183	64304273
Cardiac disorder	18.94	16.86	69	34207	55747	64408709
Blood phosphorus decreased	18.91	16.86	19	34257	5686	64458770
Systemic lupus erythematosus	18.56	16.86	9	34267	77603	64386853
Renal cyst infection	18.43	16.86	6	34270	190	64464266
Anaemia	18.27	16.86	122	34154	378558	64085898
Gangrene	18.26	16.86	21	34255	7317	64457139
Oxygen saturation decreased	18.24	16.86	18	34258	107158	64357298
Calcinosis	18.22	16.86	12	34264	1976	64462480
Joint range of motion decreased	18.17	16.86	35	34241	19308	64445148
Anaphylactic reaction	17.94	16.86	7	34269	68657	64395799
Product dispensing issue	17.93	16.86	5	34271	92	64464364
Extremity contracture	17.86	16.86	11	34265	1614	64462842
Oncocytoma	17.62	16.86	4	34272	30	64464426
Nasal congestion	17.48	16.86	5	34271	59653	64404803
Vestibular neuronitis	17.42	16.86	8	34268	648	64463808
Poor peripheral circulation	17.22	16.86	14	34262	3186	64461270
Blood glucose decreased	17.20	16.86	38	34238	23085	64441371
Hyponatraemia	17.13	16.86	33	34243	148306	64316150
Blood cholesterol increased	17.07	16.86	3	34273	50063	64414393
Depression	16.93	16.86	46	34230	183245	64281211

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H05BX01	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS CALCIUM HOMEOSTASIS ANTI-PARATHYROID AGENTS Other anti-parathyroid agents
FDA MoA	N0000020081	Increased Calcium-sensing Receptor Sensitivity
MeSH PA	D057966	Calcimimetic Agents
MeSH PA	D000077264	Calcium-Regulating Hormones and Agents
MeSH PA	D006727	Hormone Antagonists
FDA EPC	N0000175902	Calcium-sensing Receptor Agonist
CHEBI has role	CHEBI:48525	calcimimetics
CHEBI has role	CHEBI:50183	P450 inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypercalcemia due to Primary Hyperparathyroidism	indication
Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis	indication
Parathyroid Carcinoma with Hypercalcemia	indication
Hypophosphatemia	contraindication	4996001
Hypocalcemia	contraindication	5291005
Low blood pressure	contraindication	45007003
Chronic heart failure	contraindication	48447003
Seizure disorder	contraindication	128613002
Disease of liver	contraindication	235856003	DOID:409
Adynamic bone disease	contraindication	236552002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.69	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 30MG BASE	SENSIPAR	AMGEN	N021688	March 8, 2004	RX	TABLET	ORAL	7829595	Sept. 22, 2026	METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
EQ 60MG BASE	SENSIPAR	AMGEN	N021688	March 8, 2004	RX	TABLET	ORAL	7829595	Sept. 22, 2026	METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
EQ 90MG BASE	SENSIPAR	AMGEN	N021688	March 8, 2004	RX	TABLET	ORAL	7829595	Sept. 22, 2026	METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Extracellular calcium-sensing receptor	GPCR	P41180	CASR_HUMAN	POSITIVE ALLOSTERIC MODULATOR	EC50	7.70	CHEMBL	CHEMBL
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	7.30	CHEMBL
Glycine receptor subunit alpha-1	Ion channel	P23415	GLRA1_HUMAN		EC50	6.49	CHEMBL
Metabotropic glutamate receptor 5	GPCR		GRM5_RAT	ALLOSTERIC MODULATOR	Ki	4.35	IUPHAR

External reference:

ID	Source
4021430	VUID
N0000148841	NUI
D03504	KEGG_DRUG
364782-34-3	SECONDARY_CAS_RN
384379	RXNORM
4021430	VANDF
C1337242	UMLSCUI
CHEBI:48390	CHEBI
YP4	PDB_CHEM_ID
CHEMBL1201284	ChEMBL_ID
CHEMBL1200776	ChEMBL_ID
DB01012	DRUGBANK_ID
D000069449	MESH_DESCRIPTOR_UI
156419	PUBCHEM_CID
3308	IUPHAR_LIGAND_ID
8287	INN_ID
UAZ6V7728S	UNII
18133	MMSL
303128	MMSL
49840	MMSL
d05218	MMSL
008595	NDDF
008596	NDDF
409391006	SNOMEDCT_US
409392004	SNOMEDCT_US
426512007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7067	TABLET, FILM COATED	30 mg	ORAL	ANDA	25 sections
Cinacalcet	Human Prescription Drug Label	1	16714-078	TABLET, FILM COATED	30 mg	ORAL	ANDA	27 sections
Cinacalcet	Human Prescription Drug Label	1	16714-079	TABLET, FILM COATED	60 mg	ORAL	ANDA	27 sections
Cinacalcet	Human Prescription Drug Label	1	16714-080	TABLET, FILM COATED	90 mg	ORAL	ANDA	27 sections
CINACALCET	HUMAN PRESCRIPTION DRUG LABEL	1	16729-440	TABLET, FILM COATED	30 mg	ORAL	ANDA	25 sections
CINACALCET	HUMAN PRESCRIPTION DRUG LABEL	1	16729-441	TABLET, FILM COATED	60 mg	ORAL	ANDA	25 sections
CINACALCET	HUMAN PRESCRIPTION DRUG LABEL	1	16729-442	TABLET, FILM COATED	90 mg	ORAL	ANDA	25 sections
Cinacalcet	Human Prescription Drug Label	1	31722-103	TABLET, FILM COATED	30 mg	ORAL	ANDA	29 sections
Cinacalcet	Human Prescription Drug Label	1	31722-104	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Cinacalcet	Human Prescription Drug Label	1	31722-105	TABLET, FILM COATED	90 mg	ORAL	ANDA	29 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	42291-459	TABLET, FILM COATED	30 mg	ORAL	ANDA	25 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	42291-460	TABLET, FILM COATED	60 mg	ORAL	ANDA	25 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	42291-461	TABLET, FILM COATED	90 mg	ORAL	ANDA	25 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	42543-961	TABLET, FILM COATED	30 mg	ORAL	ANDA	23 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	42543-962	TABLET, FILM COATED	60 mg	ORAL	ANDA	23 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	42543-963	TABLET, FILM COATED	90 mg	ORAL	ANDA	23 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	43598-367	TABLET	30 mg	ORAL	ANDA	24 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	43598-368	TABLET	60 mg	ORAL	ANDA	24 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	43598-369	TABLET	90 mg	ORAL	ANDA	24 sections
Cinacalcet	Human Prescription Drug Label	1	47335-379	TABLET, FILM COATED	30 mg	ORAL	ANDA	27 sections
Cinacalcet	Human Prescription Drug Label	1	47335-380	TABLET, FILM COATED	60 mg	ORAL	ANDA	27 sections
Cinacalcet	Human Prescription Drug Label	1	47335-600	TABLET, FILM COATED	90 mg	ORAL	ANDA	27 sections
Sensipar	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3529	TABLET, COATED	30 mg	ORAL	NDA	28 sections
Sensipar	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4470	TABLET, COATED	30 mg	ORAL	NDA	26 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	50268-153	TABLET	30 mg	ORAL	ANDA	24 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	51407-295	TABLET, FILM COATED	30 mg	ORAL	ANDA	23 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	51407-296	TABLET, FILM COATED	60 mg	ORAL	ANDA	23 sections
Cinacalcet	HUMAN PRESCRIPTION DRUG LABEL	1	51407-297	TABLET, FILM COATED	90 mg	ORAL	ANDA	23 sections
Sensipar	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0577	TABLET, COATED	30 mg	ORAL	NDA	26 sections
Sensipar	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0578	TABLET, COATED	60 mg	ORAL	NDA	26 sections